[go: up one dir, main page]

WO2007095353A3 - Gpcrs as angiogenesis targets - Google Patents

Gpcrs as angiogenesis targets Download PDF

Info

Publication number
WO2007095353A3
WO2007095353A3 PCT/US2007/004114 US2007004114W WO2007095353A3 WO 2007095353 A3 WO2007095353 A3 WO 2007095353A3 US 2007004114 W US2007004114 W US 2007004114W WO 2007095353 A3 WO2007095353 A3 WO 2007095353A3
Authority
WO
WIPO (PCT)
Prior art keywords
angiogenesis
provides methods
gpcrs
lec3
ednra
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/004114
Other languages
French (fr)
Other versions
WO2007095353A2 (en
Inventor
Tinchung Leung
Janet D Robishaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geisinger Clinic
Original Assignee
Geisinger Clinic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geisinger Clinic filed Critical Geisinger Clinic
Priority to JP2008555380A priority Critical patent/JP2009526861A/en
Priority to EP07750916A priority patent/EP1996619A4/en
Publication of WO2007095353A2 publication Critical patent/WO2007095353A2/en
Anticipated expiration legal-status Critical
Publication of WO2007095353A3 publication Critical patent/WO2007095353A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention provides methods of modulating angiogenesis by increasing or decreasing expression or function of G-Protein Coupled Receptors (GPCRs) namely Lectomedin-3 (LEC3), Endothelin-1 Receptor (EDNRA) and C-X-C Chemokine Receptor 4 (CXCR-4). The invention also provides methods of inhibiting and promoting GPCR-dependent angiogenesis in vertebrates, particular mammals, including humans, for the treatment of angiogenesis-related diseases. The invention also provides methods of identifying compounds that promote or inhibit angiogenesis through their interaction with LEC3, EDNRA and/or CXCR-4. The invention further provides methods of modulating angiogenesis through the modulation of these GPCRs and VEGF.
PCT/US2007/004114 2006-02-14 2007-02-14 Gpcrs as angiogenesis targets Ceased WO2007095353A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2008555380A JP2009526861A (en) 2006-02-14 2007-02-14 GPCR as an angiogenic target
EP07750916A EP1996619A4 (en) 2006-02-14 2007-02-14 Gpcrs as angiogenesis targets

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77299106P 2006-02-14 2006-02-14
US60/772,991 2006-02-14

Publications (2)

Publication Number Publication Date
WO2007095353A2 WO2007095353A2 (en) 2007-08-23
WO2007095353A3 true WO2007095353A3 (en) 2009-04-16

Family

ID=38372149

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/004114 Ceased WO2007095353A2 (en) 2006-02-14 2007-02-14 Gpcrs as angiogenesis targets

Country Status (3)

Country Link
EP (1) EP1996619A4 (en)
JP (1) JP2009526861A (en)
WO (1) WO2007095353A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101756131B1 (en) 2014-09-26 2017-07-12 주식회사 바이로메드 Composition for Preventing or Treating Peripheral Artery Disease Using Hepatocyte Growth Factor and Stromal Cell Derived Factor 1 alpha
FR3077574B1 (en) 2018-02-07 2022-04-01 Commissariat Energie Atomique ANTIBODIES DIRECTED AGAINST ENDOTHELIN RECEPTOR SUBTYPE A AND THEIR USES.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5759804A (en) * 1992-11-17 1998-06-02 Icos Corporation Isolated nucleic acid encoding seven transmembrane receptors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1834197A (en) * 1996-01-30 1997-08-22 National Institutes Of Health, The Cells expressing both human cd4 and cxcr4
US6479256B1 (en) * 1998-03-04 2002-11-12 Icos Corporation Lectomedin materials and methods
WO1999047158A2 (en) * 1998-03-13 1999-09-23 The University Of British Columbia Therapeutic chemokine receptor antagonists
US20020107195A1 (en) * 1998-07-21 2002-08-08 Smithkline Beecham Corporation Method for inducing chemotaxis in endothelial cells by administering stromal cell derived factor-1alpha
JP2004531249A (en) * 2001-02-14 2004-10-14 プロテイン デザイン ラブス インコーポレイティド Method for diagnosing angiogenesis, composition, and method for screening angiogenesis modulator
US20040009171A1 (en) * 2001-10-18 2004-01-15 Genentech, Inc. Methods for the treatment of carcinoma

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5759804A (en) * 1992-11-17 1998-06-02 Icos Corporation Isolated nucleic acid encoding seven transmembrane receptors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1996619A4 *

Also Published As

Publication number Publication date
EP1996619A4 (en) 2009-11-18
WO2007095353A2 (en) 2007-08-23
JP2009526861A (en) 2009-07-23
EP1996619A2 (en) 2008-12-03

Similar Documents

Publication Publication Date Title
CL2009000171A1 (en) Compounds derived from 1-oxa-3-azaspiro, antagonists of the neuropeptide y5 receptor y (npy); pharmaceutical composition comprising said compound; and use for the treatment of eating disorders, drinking disorders, obesity, and depression.
EA201100306A1 (en) CYCLOGEXILAMIDE DERIVATIVES AND THEIR APPLICATION AS ANTAGONISTS OF CRF-1 RECEPTOR
EA201000319A1 (en) DERIVATIVES OF AZACYCLILYZYOHINOLINONE AND ISOINDOLINONE AS ANTAGONISTS OF HISTAMINE RECEPTORS OF SUBTIP 3
CL2007003266A1 (en) COMPOUNDS DERIVED FROM PROGESTERONA, ANTAGONISTS OF THE PROGESTERONE RECEIVER; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF ENDOMETRIOSIS, MYOMAS OR TUMORS DEPENDENT ON HORMONES.
WO2010016766A3 (en) Antibodies recognizing endogenous human lgr5 and/or lgr6
ATE496051T1 (en) PYRAZOLOTETRAHYDROPYRIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
BRPI0605921A2 (en) organic compounds
WO2008064054A3 (en) Compounds which modulate the cb2 receptor
WO2006009734A8 (en) Gonadotropin releasing hormone receptor antagonists
MY155621A (en) Axl antibodies
WO2007114926A3 (en) Kinase antagonists
WO2010116282A8 (en) 4, 5-dihydro-1h-pyrazole compounds and their pharmaceutical uses
ATE481405T1 (en) THIAZOLPYRAZOLOPYRIMIDINES AS ANTAGONISTS OF THE CRF1 RECEPTOR
BRPI0917661B8 (en) product, pharmaceutical composition and use of the combination of macitentan with a compound that is endowed with prostacyclin receptor agonist properties
EA200901099A1 (en) CONNECTIONS AND METHODS FOR MODULATING RECEPTORS CONNECTED WITH G-PROTEIN
FR2913358B1 (en) DEVICE FOR IGNITING AN ALUMINOTHERMAL COMPOSITION, HOLLOWING THE INCORPORATING DEVICE AND ASSOCIATED METHODS.
UY32225A (en) CICLOALCANO ANTAGONISTS [B] AZAINDOL OF PROSTAGLANDIN D2 RECEPTORS
CY1113734T1 (en) CHEMICAL COMPOUNDS
WO2006097536A3 (en) Dimeric peptide agonists of the glp-1 receptor
EA201000316A1 (en) IZOHINOLINIL AND IZINODOLINIL DERIVATIVES AS ANTAGONISTS OF HISTAMINE RECEPTORS 3 SUBTYPES
ATE458740T1 (en) 1,4,5,6,7,8-HEXAHYDRO-1,2,5-TRIAZA-AZULENE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
NO20084458L (en) IL-8 receptor antagonists
ATE484505T1 (en) 5-SULFANYLMETHYLÄ1,2,4ÜTRIAZOLÄ1,5-AUPYRIMIDINE- - OLDERIVATES AS CXCR2 ANTAGONISTS
ATE496916T1 (en) QUINICLIDINE DERIVATIVES OF (HETERO)ARYLCYCLOHEPTANCARBOXIC ACIDS AS ANTAGONISTS ON THE MUSCARIN RECEPTOR
WO2009089234A3 (en) Substituted dibenzhydrylpiperazines

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2008555380

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007750916

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07750916

Country of ref document: EP

Kind code of ref document: A2